Autopsy report · NCT04342156

Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19

“The number of patients with COVID-19 in Singapore was coming down for the community and the concerns about the potential side effects particularly when the baseline ECG and serum electrolytes was not proposed.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Tan Tock Seng Hospital

Sponsor type

University, hospital or other

Conditions

Coronavirus Infection; Hydroxychloroquine Adverse Reaction

Interventions

Hydroxychloroquine Sulfate 200 milligram (mg) Tab

Participants

0

Trials that died the same way

• Ultrasonography in Norwegian Emergency Department Patients With Suspected Covid-19 Infection
  “lack of Covid-19 patients” (63% match in meaning)
• Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19
  “Based on current epidemic situation in China, there is few Mild and Moderate COVID-19 patients.” (61% match in meaning)
• Non Verbal Communication and Dementia
  “health context of covid-19” (59% match in meaning)
• Ivermectin in Adults With Severe COVID-19.
  “Lack of severe COVID-19 cases in the place of study” (57% match in meaning)
• Pedicle Osteotomy for Stenosis Trial
  “In light of the ongoing COVID-19 pandemic and its impact on clinical trials” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.